Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

PURPOSE: Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS: We constructed a Markov model to assess the cost-effect...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res Treat
Autori principali: Diaby, Vakaramoko, Adunlin, Georges, Ali, Askal A., Zeichner, Simon B., de Lima Lopes, Gilberto, Kohn, Christine G., Montero, Alberto J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5329168/
https://ncbi.nlm.nih.gov/pubmed/27654970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3978-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi